Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02404077

Enrollment

712

Registered

2015-03-31

Start date

2015-04-30

Completion date

2017-03-31

Last updated

2017-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation

Keywords

Patients, undergoing, ICU

Brief summary

The investigators' clinical practice makes use of oral clonidine as a means of transitioning from intravenous dexmedetomidine following prolonged infusions (more than 3-5 days). Although this is common clinical practice, there is limited clinical data to demonstrate the efficacy of this technique and to provide clonidine dosing guidelines. The purpose of this study is to retrospectively review the investigators' experience with the use of oral clonidine to prevent withdrawal following the prolonged administration of dexmedetomidine.

Interventions

DRUGClonidine

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients who received clonidine during the transition from dexmedetomidine.

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Evidence of withdrawal	Twice a day from the first day of taper of dexmedetomidine until 72 hrs. after the last dose	Withdrawal is assessed using the Withdrawal Assessment Tool-1 (WAT-1). The 19-item assessment consists of (1) a review of the patient's record for the past 12 hours, (2) direct observation of the patient for 2 minutes, (3) patient assessment during a progressive stimulated exam routinely performed to assess level of consciousness at the beginning of each 12-hour shift, and finally (4) assessment of post-stimulus recovery.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026